A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer

Michael V. Seiden, Alan N. Gordon, Diane C. Bodurka, Ursula A. Matulonis, Richard T. Penson, Eddie Reed, David S Alberts, Garry Weems, Michael Cullen, William P. McGuire

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective. To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive prior chemotherapy. Methods. The trial was an open label phase II study. Patients initially enrolled in this study were treated every 14 days with a dose of 24 mg/m2. Unexpected retinal toxicity associated with this dose and schedule lead to modification of the dosing to 0.55 mg/kg on the same schedule with a maximum individual dose of 50 mg. Dose reductions were permitted based on both hematologic and non-hematologic toxicities. Results. Seventy-four women were accrued and stratified into two cohorts including 58 women with platinum-resistant disease and 16 with platinum-sensitive disease. Non-hematologic toxicities included nausea, vomiting, and fatigue. Thirty-one women had between one and six visual symptoms, most were Grade 1 and 2 in nature. The majority of visual toxicities resolved either during treatment or post-treatment with irofulven. There was one partial response in each cohort with 19 (33%) and 8 (50%) of women having stable disease in the platinum-resistant and platinum-sensitive cohorts, respectively. Conclusions. Irofulven at 24 mg/m2 on every 14-day schedule is associated with significant retinal toxicity in this patient population. Dosing at 0.55 mg/kg has persistent retinal toxicity, yet demonstrated only limited anti-tumor activity in a population of women who had received extensive prior chemotherapy.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalGynecologic Oncology
Volume101
Issue number1
DOIs
StatePublished - Apr 2006

Fingerprint

Ovarian Neoplasms
Platinum
Appointments and Schedules
Drug Therapy
Nausea
Population
Vomiting
Fatigue
irofulven
Safety
Therapeutics
Neoplasms

Keywords

  • Irofulven
  • MGI-114
  • Ovarian cancer
  • Phase II trial
  • Recurrent disease
  • Visual toxicity

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Seiden, M. V., Gordon, A. N., Bodurka, D. C., Matulonis, U. A., Penson, R. T., Reed, E., ... McGuire, W. P. (2006). A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecologic Oncology, 101(1), 55-61. https://doi.org/10.1016/j.ygyno.2005.09.036

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. / Seiden, Michael V.; Gordon, Alan N.; Bodurka, Diane C.; Matulonis, Ursula A.; Penson, Richard T.; Reed, Eddie; Alberts, David S; Weems, Garry; Cullen, Michael; McGuire, William P.

In: Gynecologic Oncology, Vol. 101, No. 1, 04.2006, p. 55-61.

Research output: Contribution to journalArticle

Seiden, MV, Gordon, AN, Bodurka, DC, Matulonis, UA, Penson, RT, Reed, E, Alberts, DS, Weems, G, Cullen, M & McGuire, WP 2006, 'A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer', Gynecologic Oncology, vol. 101, no. 1, pp. 55-61. https://doi.org/10.1016/j.ygyno.2005.09.036
Seiden, Michael V. ; Gordon, Alan N. ; Bodurka, Diane C. ; Matulonis, Ursula A. ; Penson, Richard T. ; Reed, Eddie ; Alberts, David S ; Weems, Garry ; Cullen, Michael ; McGuire, William P. / A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. In: Gynecologic Oncology. 2006 ; Vol. 101, No. 1. pp. 55-61.
@article{c53e116ae4de41869724c604c35255ae,
title = "A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer",
abstract = "Objective. To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive prior chemotherapy. Methods. The trial was an open label phase II study. Patients initially enrolled in this study were treated every 14 days with a dose of 24 mg/m2. Unexpected retinal toxicity associated with this dose and schedule lead to modification of the dosing to 0.55 mg/kg on the same schedule with a maximum individual dose of 50 mg. Dose reductions were permitted based on both hematologic and non-hematologic toxicities. Results. Seventy-four women were accrued and stratified into two cohorts including 58 women with platinum-resistant disease and 16 with platinum-sensitive disease. Non-hematologic toxicities included nausea, vomiting, and fatigue. Thirty-one women had between one and six visual symptoms, most were Grade 1 and 2 in nature. The majority of visual toxicities resolved either during treatment or post-treatment with irofulven. There was one partial response in each cohort with 19 (33{\%}) and 8 (50{\%}) of women having stable disease in the platinum-resistant and platinum-sensitive cohorts, respectively. Conclusions. Irofulven at 24 mg/m2 on every 14-day schedule is associated with significant retinal toxicity in this patient population. Dosing at 0.55 mg/kg has persistent retinal toxicity, yet demonstrated only limited anti-tumor activity in a population of women who had received extensive prior chemotherapy.",
keywords = "Irofulven, MGI-114, Ovarian cancer, Phase II trial, Recurrent disease, Visual toxicity",
author = "Seiden, {Michael V.} and Gordon, {Alan N.} and Bodurka, {Diane C.} and Matulonis, {Ursula A.} and Penson, {Richard T.} and Eddie Reed and Alberts, {David S} and Garry Weems and Michael Cullen and McGuire, {William P.}",
year = "2006",
month = "4",
doi = "10.1016/j.ygyno.2005.09.036",
language = "English (US)",
volume = "101",
pages = "55--61",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer

AU - Seiden, Michael V.

AU - Gordon, Alan N.

AU - Bodurka, Diane C.

AU - Matulonis, Ursula A.

AU - Penson, Richard T.

AU - Reed, Eddie

AU - Alberts, David S

AU - Weems, Garry

AU - Cullen, Michael

AU - McGuire, William P.

PY - 2006/4

Y1 - 2006/4

N2 - Objective. To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive prior chemotherapy. Methods. The trial was an open label phase II study. Patients initially enrolled in this study were treated every 14 days with a dose of 24 mg/m2. Unexpected retinal toxicity associated with this dose and schedule lead to modification of the dosing to 0.55 mg/kg on the same schedule with a maximum individual dose of 50 mg. Dose reductions were permitted based on both hematologic and non-hematologic toxicities. Results. Seventy-four women were accrued and stratified into two cohorts including 58 women with platinum-resistant disease and 16 with platinum-sensitive disease. Non-hematologic toxicities included nausea, vomiting, and fatigue. Thirty-one women had between one and six visual symptoms, most were Grade 1 and 2 in nature. The majority of visual toxicities resolved either during treatment or post-treatment with irofulven. There was one partial response in each cohort with 19 (33%) and 8 (50%) of women having stable disease in the platinum-resistant and platinum-sensitive cohorts, respectively. Conclusions. Irofulven at 24 mg/m2 on every 14-day schedule is associated with significant retinal toxicity in this patient population. Dosing at 0.55 mg/kg has persistent retinal toxicity, yet demonstrated only limited anti-tumor activity in a population of women who had received extensive prior chemotherapy.

AB - Objective. To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive prior chemotherapy. Methods. The trial was an open label phase II study. Patients initially enrolled in this study were treated every 14 days with a dose of 24 mg/m2. Unexpected retinal toxicity associated with this dose and schedule lead to modification of the dosing to 0.55 mg/kg on the same schedule with a maximum individual dose of 50 mg. Dose reductions were permitted based on both hematologic and non-hematologic toxicities. Results. Seventy-four women were accrued and stratified into two cohorts including 58 women with platinum-resistant disease and 16 with platinum-sensitive disease. Non-hematologic toxicities included nausea, vomiting, and fatigue. Thirty-one women had between one and six visual symptoms, most were Grade 1 and 2 in nature. The majority of visual toxicities resolved either during treatment or post-treatment with irofulven. There was one partial response in each cohort with 19 (33%) and 8 (50%) of women having stable disease in the platinum-resistant and platinum-sensitive cohorts, respectively. Conclusions. Irofulven at 24 mg/m2 on every 14-day schedule is associated with significant retinal toxicity in this patient population. Dosing at 0.55 mg/kg has persistent retinal toxicity, yet demonstrated only limited anti-tumor activity in a population of women who had received extensive prior chemotherapy.

KW - Irofulven

KW - MGI-114

KW - Ovarian cancer

KW - Phase II trial

KW - Recurrent disease

KW - Visual toxicity

UR - http://www.scopus.com/inward/record.url?scp=33644504528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644504528&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.09.036

DO - 10.1016/j.ygyno.2005.09.036

M3 - Article

C2 - 16260029

AN - SCOPUS:33644504528

VL - 101

SP - 55

EP - 61

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -